Last reviewed 2026-04-23 · How we verify

IPV-Al SSI

IPV-Al SSI is an inactivated poliovirus vaccine formulated with aluminum adjuvant to stimulate immune response against poliovirus types 1, 2, and 3.

IPV-Al SSI is an inactivated poliovirus vaccine formulated with aluminum adjuvant to stimulate immune response against poliovirus types 1, 2, and 3. Used for Poliomyelitis prevention in pediatric and adult populations.

At a glance

Mechanism of action

This vaccine contains chemically inactivated poliovirus particles that cannot cause disease but trigger adaptive immune responses. The aluminum adjuvant enhances the immunogenicity of the vaccine by promoting T-cell and B-cell activation, leading to production of neutralizing antibodies against poliovirus. The vaccine is designed to provide protection against poliomyelitis through humoral and cellular immunity.

Approved indications

• Poliomyelitis prevention in pediatric and adult populations

Common side effects

• Injection site pain or swelling
• Fever
• Myalgia
• Fatigue

Key clinical trials

• Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months (PHASE3)
• Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age (PHASE3)
• 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents (PHASE1, PHASE2)
• 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants (PHASE2)
• Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.